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Abstract. The effect of Bacillus-Calmette-Guerin (BCG) on the growth of an adeno-
carcinoma of the lung induced in a Syrian hamster was evaluated. It inhibited intra-
dermal growth of the tumor when the tumor cells were mixed with high doses of BCG
prior to intradermal injection. The development of lung metastasis after excision of
the primary intradermal tumor was inhibited by BCG at doses 100 times lower than
those used to inhibit the growth of intradermal tumors. The results suggest that
effective immunotherapy may depend on the number of viable BCG cells, the route of
administration, and the anatomic location of the tumor.
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Syrian golden hamsters when treated
intratracheally with benzo(a)pyrene and
iron oxide develop respiratory tract ma-
lignancies which for the most part re-
semble the majority of human lung can-
cers both in location and morphologic
characteristics (Saffiotti et al 1968). We
have been assessing the effects of BCG
preparations on the development of pri-
mary lung tumors (Zwilling et al 1977)
and have sought in this study to assess
the effect of BCG on the growth and
metastasis of a transplantable hamster
lung adenocarcinoma induced by the
intratracheal application of the carcino-
genic agent benzo(a)pyrene.
MATERIALS AND METHODS
Animals. Inbred male Syrian golden ham-
sters, strain LSH/LAK, were obtained from
Charles River Lakeview (Lakeview, N.J.).
Animals were housed 5 per cage under standard
laboratory conditions and were used when 7-12
weeks of age.
Tumor cells. The tumor cell line used in this
study was a bronchogenic adenocarcinoma,
designated LG 1002. It was induced in an out-
bred Syrian golden hamster by the intra-
tracheal instillation of benzo(a)pyrene ad-
sorbed to ferric oxide particles and suspended
in saline (Saffiotti et al 1968). The tumor was
maintained by serial passage in the hamster
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cheek pouch. Tumor cell inocula were pre-
pared from the 2nd to 10th transplant genera-
tions by digesting small tumor pieces with
trypsin and suspending the cells at the desired
concentration in Hank's balanced salt solution
(HBSS).
Mycobacterial antigen. The Phipps strain of
Mycobacterium bovis, strain Bacillus-Calmette-
Guerin (BCG), TMC#1029, Lot #NC734A was
obtained from the Trudeau Institute (Saranac
Lake, N.Y.). Vials containing 1.2 x 108 colony
forming units (cfu) were stored frozen at—70 °C.
Dilutions of the BCG for injection were made in
Hank's BSS. Concentration of the BCG sus-
pension was accomplished by centrifugation at
200Xg for 20 minutes.
Immunizations. Tumor cell inoculations were
given intradermally in the intrascapular region
of the back or into the hind footpad of animals
anesthetized with Brevitol Sodium. Locally
administered BCG was admixed with the tu-
mor cell inoculum prior to injection. Intra-
tracheal injections of BCG were performed by
the method described by Saffiotti et al (1968)
for carcinogen instillation.
Monitoring of tumor growth. Growth of the
tumor cell inocula given intradermally in the
back was monitored by measuring the greatest
and the least diameters of the tumor nodule
with calipers. Tumor size was expressed as
the product of the two diameters. Tumor
growth in animals receiving footpad injections
was monitored by measuring the footpad thick-
ness with calipers. Footpad tumor growth was
expressed as a tumor index which was calculated
as the ratio of the thickness of the injected
footpad to the thickness of the uninjected
footpad.
Intradermal tumors were excised along with
sufficient surrounding skin to insure the com-
plete removal of the primary tumor mass. The
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wound was inspected for the presence of sub-
cutaneous tumor growth and the edges were
apposed and fastened with sterile skin clips,
which were removed 7-10 days later. Animals
were checked daily for regrowth of the tumor
at the excision site. To enumerate the number
of metastases, the lungs were cleared of blood
by severing the dorsal aorta and injecting 3-5
ml of saline into the right ventricle. They
were then removed, fixed as described by Wil-
liams and Nettersheim (1973) and strained and
cleared according to the method of Yuhas
(1973). Mean tumor sizes and number of
metastases were compared using the Student's
t-test. Tumor incidence was compared using
the Fisher's exact test.
RESULTS
BCG on the growth of intradermal tu-
mors. Animals received either 6 x 106,
1 x 107 or 6 x 1()7 cfu BCG admixed with
either 1 x 104 or 1 x 1()5 tumor cells. The
growth rate of tumors in animals injected
with 105 tumor cells is shown in figure 1.
The growth of tumors in all 3 BCG-
treated groups was significantly inhibited
after (P< 0.025) compared to the control
group. One of 5 animals in the 6 x 107
BCG group and 1 of 3 in the 107 BCG
group failed to develop tumors. Tumors
which did develop in these groups grew
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at a slower rate than did the control tu-
mors. All animals receiving 6 x 106 BCG
developed tumors; tumor appearance was
delayed and growth rate decreased.
Similar results were obtained when BCG
was admixed with 1 x 104 tumor cells.
BCG on the growth of tumors inoculated
into the footpad. Since the skin of most
rodents does not lend itself to a vigorous
delayed-type inflammatory response, the
footpad was studied as an alternate site
of inoculation. In this experiment, 104
tumor cells were admixed with 105 to 107
cfu BCG and injected into the hind foot-
pad of the hamsters. Injection of 104
tumor cells alone and 107 cfu BCG alone
served as controls. Tumor growth was
measured as the ratio of the thickness of
the tumor injected footpad to the unin-jected footpad. The results, expressed
as a tumor index, are shown in figure 2.
At days 30 and 37, the mean tumor indices
for the groups receiving 1()4 and 107 cfu
BCG were significantly smaller (P<0.05)
when compared to the tumor control
group. By day 42, all of the BCG-
treated groups had significantly smaller
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FIGURE 1. Effect of BCG on the growth of LG1002 tumors. Varying numbers of BCG
were admixed with 1 x 105 LG1002 tumor cells and inoculated intradermally and tumor growth
was monitored for 45 days.
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FIGURE 2. Growth of LG1002 tumor cells following footpad inoculation of BCG-tumor cell
mixtures. Numbers in parenthesis denote number of animals with tumor/number inoculated.
1 xlO4 LG1002 cells were admixed with varying numbers of BCG and tumor growth was moni-
tored for 42 days.
(P<0.01) tumors compared to the con-
trols. Footpad swelling in animals re-
ceiving 107 BCG mixed with 104 tumor
cells was observed to be comparable in
size to that seen in animals receiving 107
BCG alone. All animals receiving 107
BCG failed to develop tumors and the
tumor incidence in animals receiving
other doses of BCG varied from 20% to
BCG on the development of pulmonary
metastasis. Studies of the effect of BCG
on lung metastasis were initiated because
of our observation that intradermal in-jection of LG1002 tumor cells resulted in
numerous metastases to the lung. In
preliminary experiments we determined
that lower doses of BCG were more ef-
fective at reducing the number of
metastases than higher doses and that
BCG treatment was more effective when
administered after excision of the pri-
mary tumor rather than at the same time
or prior to excision.
Table 1 shows the results of an experi-
ment in which 1 x 104 cfu BCG was in-jected intratracheally on the same day as
tumor excision or 1 or 2 weeks following
excision. Three weeks after excision
TABLE 1
The effect of intratracheal BCG on the
development of lung metastasis*
Week of BCG
Admin. No. Animals
No. Lung
Metastasis
0
1
2
Untreated
11
11
6
13
85.2±25
86.7±17
39.3± 9**
106.7±20
*Groups of hamsters were injected intra-
dermally with 5 x 10" LG1002 tumor cells.
Four weeks later the primary tumor was
excised and 1 x 104 cfu BCG injected intra-
tracheally on the same day as excision or 1 or
2 weeks following excision. On the third
week following tumor excision, the animals
were sacrificed and the number of metastases
per lung enumerated.
**P<0.05.
animals were sacrificed and the mean
number of metastases per lung in animals
not receiving BCG was 106.7. When
animals were treated with BCG at the
time of excision or one week following
tumor excision, the number of metastases
per lung was reduced to 85.2 and 86.7
respectively. When treatment was de-
layed until 2 weeks following excision of
the primary tumor, the mean number of
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metastases per lung was significantly re-
duced to 39.3 (P<0.05).
DISCUSSION
Suppression of tumor growth by BCG
was observed to be dose related, higher
doses of BCG being more effective. The
minimum dose of BCG that significantly
suppressed intradermal tumors was 6 x
106 cfu. This finding is consistant with
those of others (Baldwin and Pimm 1973,
Harmel el al 1973, Kreider et al 1976,
Zbar et al 1971). Barlett et al (1970)
have shown that the ratio of BCG to
tumor cells may be as important as the
absolute number of BCG; high BCG to
tumor cell ratios were inhibitory while
lower ratios gave little protection.
An increase in the effectiveness of BCG-
mediated inhibition of tumor growth was
noted when the BCG-tumor cell mixture
was inoculated into the footpad of the
hamster. Significant tumor suppression
was observed in the footpad at doses of
BCG less than that required for suppres-
sion of intradermal growth. An intense
inflammatory reaction to the injection of
BCG alone was also observed.
BCG was generally more effective at
inhibiting the development of lung meta-
tases when given after excision of the
primary tumor. These findings are in
agreement with those of Sparks et al
(1973) in which postoperative immuno-
therapy with subcutaneous injections of
BCG or BCG tumor cell vaccine re-
sulted in a significant increase in the
median survival time. Proctor et al
(1976), however, have reported that BCG
given 10 days prior to subcutaneous
tumor inoculation was generally more
effective in inhibiting the development of
lung metastases than BCG given on the
same day or 10 days after tumor. In
our studies the dose of BCG found to be
most effective in inhibiting metastases
was at least 100 fold less than the effec-
tive dose found to inhibit the growth of
intradermal tumors.
The mechanism by which BCG affects
tumor growth appears to be complex in
nature. It has been suggested that lym-
phocytes reacting to BCG antigens may
nonspecifically destory tumor cells
(Meltzer et al 1976). During the course
of this reaction, lymphocytes may also
produce a variety of lymphokines that re-
sult in activation of macrophages (Fidler
et al 1976, Kripke et al 1977). It has been
reported by Zwilling and Campolito
(1977) and Hibbs et al (1972) that macro-
phages activated as a result of BCG in-
fection acquire the capacity to destroy
a variety of tumor cells. The results of
our investigation indicate that the in-
flammatory response induced by BCG
may differ depending on anatomical loca-
tion. Effective immunotherapy using
agents such as BCG may depend on the
number of viable organisms and the route
of administration.
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